Monthly Archives: March 2014

Nine species of giant, flightless birds, known as moas, suddenly went extinct within two centuries of humans first arrival to New Zealand. Coincidence? No, a team of geneticists, biologists and archeologists recently wrote. The scientists found evidence that moas thrived before Polynesians colonized the islands in the 13th century.

The scientists analyzed genetic remains from 281 individual birds from four species of moa. The researchers looked for signs of dwindling moa populations in the 4,000 years before humans arrived. When animal populations shrink dramatically, their genetic diversity also decreases. Instead, the moa had a healthy variety of DNA, which suggested strong populations.

CSI Fossils: Ancient Killers Caught in the Act

For example, the 3.6 meter (12 ft.) tall South Island giant moa (Dinornis robustus) had an estimated population of 9,200 individuals that may have been growing. Although another species, the 1.5 to 1.8 meter (4.95.9 ft.) tall eastern moa (Euryapteryx crassus), showed signs of a major historical die-off, that reduction in numbers likely occurred more than 17,900 years ago, thousands of years before humans arrived. Euryapteryx crassus had recovered and seemed to be thriving in the eastern lowland forests of New Zealand by the time humans arrived.

BLOG: Humans Acquitted of Mammoth Murder

These findings point strongly toward human contact as the only factor responsible for the extinction, wrote the scientists in Proceedings of the National Academy of Sciences.

Elsewhere the situation may be more complex, but in the case of New Zealand the evidence provided by ancient DNA is now clear: The megafaunal extinctions were the result of human factors, said lead author Mike Bunce of Curtin University in Australia in a press release. We need to be more aware of the impacts we are having on the environment today and what we, as a species, are responsible for in the past.

Illustration: Polynesians Hunting Giant Moa, by Heinrich Harder. Credit: Wikimedia Commons

The rest is here:
Humans Wiped Out Giant New Zealand Bird

PUBLIC RELEASE DATE:

19-Mar-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, March 19, 2014The number of menopausal women is projected to reach 50 million by 2020. With changing views on appropriate therapies to control symptoms and new treatments available and on the horizon, most internists lack the core competencies and experience to meet the needs of women entering menopause, according to a provocative Commentary published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh.

The article "Competency in Menopause Management: Whither Goest the Internist?" by Richard Santen, MD, University of Virginia Health Sciences System (Charlottesville), Cynthia Stuenkel, MD, University of California at San Diego, Henry Burger, MD, Monash University (Melbourne, Australia), and JoAnn Manson, MD, Brigham and Women's Hospital, Harvard Medical School (Boston, MA), describes the changing landscape of menopausal symptom management, with renewed use of hormone therapy among recently menopausal women at low risk of breast cancer and heart disease. The emergence of new non-hormonal treatments and other approaches may be unfamiliar to internists who are often ill-prepared to manage symptoms in women who have completed their reproductive years and are approaching or beginning menopause.

"It is essential that new curricula be developed to train internists in the core competencies needed to manage menopausal symptoms," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the official journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Academy

See original here:
Internists must play a larger role in managing menopausal symptoms

Mar 19, 2014 by Robert Sanders Human cardiac myocytes (muscle cells) stained green for proteins encoded by edited genes using the new CRISPR/Cas9 technology.

The University of California, Berkeley, and UC San Francisco are launching the Innovative Genomics Initiative (IGI) to lead a revolution in genetic engineering based on a new technology already generating novel strategies for gene therapy and the genetic study of disease.

The Li Ka Shing Foundation has provided a $10 million gift to support the initiative, establishing the Li Ka Shing Center for Genomic Engineering and an affiliated faculty chair at UC Berkeley. The two universities also will provide $2 million in start-up funds.

At the core of the initiative is a revolutionary technology discovered two years ago at UC Berkeley by Jennifer A. Doudna, executive director of the initiative and the new faculty chair. The technology, precision "DNA scissors" referred to as CRISPR/Cas9, has exploded in popularity since it was first published in June 2012 and is at the heart of at least three start-ups and several heavily-attended international meetings. Scientists have referred to it as the "holy grail" of genetic engineering and a "jaw-dropping" breakthrough in the fight against genetic disease. In honor of her discovery and earlier work on RNA, Doudna received last month the Lurie Prize of the Foundation for the National Institutes of Health.

"Professor Doudna's breakthrough discovery in genomic editing is leading us into a new era of possibilities that we could have never before imagined," said Li Ka-shing, chairman of the Li Ka Shing Foundation. "It is a great privilege for my foundation to engage with two world-class public institutions to launch the Innovative Genomics Initiative in this quest for the holy grail to fight genetic diseases."

In the 18 months since the discovery of this technology was announced, more than 125 papers have been published based on the technique. Worldwide, researchers are using Cas9 to investigate the genetic roots of problems as diverse as sickle cell anemia, diabetes, cystic fibrosis, AIDS and depression in hopes of finding new drug targets. Others are adapting the technology to reengineer yeast to produce biofuels and wheat to resist pests and drought.

"We now have a very easy, very fast and very efficient technique for rewriting the genome, which allows us to do experiments that have been impossible before," said Doudna, a professor of molecular and cell biology in the California Institute for Quantitative Biosciences (QB3) and an investigator in the Howard Hughes Medical Institute at UC Berkeley. "We are grateful to Mr. Li Ka-shing for his support of our initiative, which will propel ground-breaking advances in genomic engineering."

Transforming genetic research

The new genomic engineering technology significantly cuts down the time it takes researchers to test new therapies. CRISPR/Cas 9 allows the creation in weeks rather than years of animal strains that mimic a human disease, allowing researchers to test new therapies. The technique also makes it quick and easy to knock out genes in human cells or in animals to determine their function, which will speed the identification of new drug targets for diseases.

"The CRISPR/Cas9 technology is a complete game changer," said Jonathan Weissman, codirector of the initiative and professor of cellular and molecular pharmacology in the UCSF School of Medicine. "With CRISPR, we can now turn genes off or on at will. I am particularly interested in using CRISPR to understand the normal functions of genes as well as how disease-causing mutations alter these functions."

Continue reading here:
New DNA-editing technology spawns novel strategies for gene therapy